Protagonist Therapeutics Inc (PTGX)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The days of sales outstanding (DSO) ratio for Protagonist Therapeutics Inc for the provided periods shows that the company did not report specific values but rather dashes ("— days") for each reporting date up to December 31, 2024. This lack of data on DSO makes it challenging to analyze the efficiency of Protagonist Therapeutics in collecting its accounts receivable.
In general, DSO is a critical metric used to assess how effectively a company is managing its accounts receivable. A lower DSO indicates a more efficient collections process, as the company is able to convert its accounts receivable into cash quickly. Conversely, a high DSO could suggest potential issues with credit policies, collection procedures, or customer creditworthiness.
Without specific DSO values for Protagonist Therapeutics, it is not possible to evaluate the company's performance in managing its accounts receivable over time. In future analyses, obtaining actual DSO figures would provide valuable insights into the company's financial health and efficiency in collecting outstanding receivables.
Peer comparison
Dec 31, 2024